Covaxin to Be Evaluated as COVID-19 Vaccine Candidate in US, Says Bharat Biotech
"Ocugen, Inc (NASDAQ: OCGN) announced that the US Food and Drug Administration (FDA) has lifted its clinical hold on the Company's Investigational New Drug application (IND) to evaluate the COVID-19 vaccine candidate, BBV152, known as Covaxin outside the United States.
Hyderabad, February 19: Hyderabad-based Bharat Biotech on Saturday said its COVID-19 vaccine Covaxin will be evaluated as a vaccine candidate for the disease in the United States.
"Ocugen, Inc (NASDAQ: OCGN) announced that the US Food and Drug Administration (FDA) has lifted its clinical hold on the Company's Investigational New Drug application (IND) to evaluate the COVID-19 vaccine candidate, BBV152, known as Covaxin outside the United States. Ocugen, Inc is co-developing Bharat Biotech's Covaxin vaccine candidate for COVID-19 in USA and Canada," reads Bharat Biotech's statement. More Than 175.03 Crore Coronavirus Vaccine Doses Administered In The Country So Far.
Earlier the Ministry of Health and Family Welfare had informed that Covaxin has been granted approval for emergency use in 13 countries as of January 31, 2022.
(This is an unedited and auto-generated story from Syndicated News feed, LatestLY Staff may not have modified or edited the content body)